| human | Q5 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q46640479 | A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests |
| Q36191044 | A review of clozapine safety |
| Q44289696 | Altered pain sensitivity and morphine-induced anti-nociception in mice lacking CCK2 receptors |
| Q26781104 | Animal models for screening anxiolytic-like drugs: a perspective |
| Q37012097 | Animal models of anxiety in mice |
| Q44366974 | Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice |
| Q40744982 | Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. |
| Q46629165 | Antidepressant-like effect of lamotrigine is reversed by veratrine: a possible role of sodium channels in bipolar depression |
| Q44325070 | Antidepressant-like effects in various mice strains in the forced swimming test. |
| Q44538027 | Antidepressant-like effects in various mice strains in the tail suspension test |
| Q45181156 | Anxiolytic profile of HG1, a 5-HT-moduline antagonist, in three mouse models of anxiety |
| Q48335042 | Anxiolytic-like effect of 5-HT(2) ligands and benzodiazepines co-administration: comparison of two animal models of anxiety (the four-plate test and the elevated plus maze). |
| Q46551041 | Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action |
| Q44366984 | Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety |
| Q46836121 | Anxiolytic-like effects of DOI microinjections into the hippocampus (but not the amygdala nor the PAG) in the mice four plates test |
| Q45973903 | Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. |
| Q37686937 | Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition |
| Q36801857 | Bipolar disorder: how far are we from a rigorous definition and effective management? |
| Q45970913 | Brain structures implicated in the four-plate test in naïve and experienced Swiss mice using injection of diazepam and the 5-HT2A agonist DOI. |
| Q33661489 | Can Antipsychotic Agents be Considered as Real Antimanic Treatments? |
| Q39775451 | Clonidine potentiates the effects of tranylcypromine, phenelzine and two analogues in the forced swimming test in mice |
| Q35952682 | Dopamine, depression and antidepressants |
| Q79463878 | Effect of GABAergic ligands on the anxiolytic-like activity of DOI (a 5-HT(2A/2C) agonist) in the four-plate test in mice |
| Q28574188 | Effect of intraperitoneal mRNA antisense-oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats: association with pre-experimental stress |
| Q46819541 | Effect of noradrenergic system on the anxiolytic-like effect of DOI (5-HT2A/2C agonists) in the four-plate test |
| Q44682623 | Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice |
| Q42257957 | Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test |
| Q44109295 | Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance |
| Q28299108 | Forced swimming test in mice: a review of antidepressant activity |
| Q36568973 | How assess drugs in the treatment of acute bipolar mania? |
| Q44697787 | Impacts of the new flunitrazepam regulations on the consumption of hypnotics |
| Q46431169 | Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test |
| Q43223693 | Implication of 5-HT2 receptor subtypes in the mechanism of action of the GABAergic compound etifoxine in the four-plate test in Swiss mice |
| Q46695971 | Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice |
| Q44014662 | Improved efficacy of fluoxetine in increasing hippocampal 5-hydroxytryptamine outflow in 5-HT(1B) receptor knock-out mice |
| Q46468570 | Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? |
| Q45180504 | Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test? |
| Q44152059 | Lamotrigine-induced neutropenia following two attempts to increase dosage above 50 mg/day with recovery between episodes |
| Q46705516 | Light/dark cycle manipulation influences mice behaviour in the elevated plus maze |
| Q34474219 | Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study |
| Q37481986 | Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression |
| Q44546664 | Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. |
| Q43982785 | Negative symptoms, depression and Alzheimer's disease |
| Q34689662 | New challenges for translational psychopharmacology |
| Q35157387 | Nicotinic receptors and Alzheimer's disease |
| Q35841683 | Nicotinic receptors and schizophrenia |
| Q44905262 | No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors |
| Q35011794 | Pharmacotherapy of anxious disorders |
| Q35825523 | Population pharmacokinetics of ceftazidime in burn patients |
| Q35688601 | Population pharmacokinetics of imipenem in burn patients |
| Q37993969 | Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal. |
| Q38635792 | Potential serotonergic agents for the treatment of schizophrenia |
| Q36395651 | Potentiation of antidepressant-like activity with lithium: mechanism involved |
| Q35922178 | Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. |
| Q44564810 | Rhabdomyolysis in cardiac transplant recipient due to verapamil interaction with simvastatin and cyclosporin treatment |
| Q45255966 | Role of GABA-ergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze |
| Q35006965 | SNRIs: mechanism of action and clinical features |
| Q35679966 | Sedation, an unpleasant, undesirable and potentially dangerous side-effect of many psychotropic drugs |
| Q41943252 | Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system |
| Q46511484 | The four-plates test-retest paradigm to discriminate anxiolytic effects |
| Q50939496 | The four-plates test: anxiolytic or analgesic paradigm? |
| Q35071479 | The mouse light/dark box test |
| Q28269179 | The other face of depression, reduced positive affect: the role of catecholamines in causation and cure |
| Q36803109 | The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders |
| Q37585387 | The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers |
| Q43297492 | Topiramate and phenytoin anti-immobility effect in the mice forced swimming test is reversed by veratrine: Implication for bipolar depression treatment |
| Q44697803 | Tramadol and oral anticoagulants: interaction or confounding factors? |
| Q35965556 | Treatment of acute mania--from clinical trials to recommendations for clinical practice |
| Q35097518 | Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review |
| Q46635311 | alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice |
Search more.